Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Fatigue is a common symptom in primary biliary cirrhosis (PBC). In animal models of cholestasis, abnormalities in serotonin neurotransmission are observed with fatigue. The role of selective serotonin reuptake inhibitors in fatigue-related PBC, however, is unknown. A double-blind, placebo-controlled study design was conducted to determine the safety and efficacy of fluoxetine for the treatment of fatigue in PBC. Patients were randomized to fluoxetine, 20 mg daily, or matched placebo for 8 weeks' duration. Fatigue was assessed by the Fisk Fatigue Impact Scale (FFIS). The primary study endpoint was a > or =50% reduction in overall FFIS score at the end of treatment. Health-related quality of life (HRQL) was assessed as a secondary endpoint. Among 220 consecutively screened patients, only 18 (9%) eligible individuals were randomized to fluoxetine (n=10) or placebo (n=8) for 8 weeks. Baseline variables including median FFIS scores (52 vs 42; P=0.21) were similar between treatment arms (P > 0.05). After 8 weeks of therapy, no statistically significant change in median FFIS score was observed in the fluoxetine group. Median FFIS score in the placebo group was reduced (42 to 28), but not statistically significant. No difference in HRQL was observed between treatment arms after 8 weeks. Fourteen (78%) patients completed therapy, while four (22%) individuals withdrew from the trial. Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Altered serotonin neurotransmission may mediate fatigue in chronic liver disease (183) ; however, ondansetron, an antagonist to serotonin receptor, did not relieve fatigue in a clinical trial.(184)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [184]
Citations
Cites
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267 · cited 7×
“%) individuals were not randomized based on scores ≥16 points on the CES-D questionnaire.”
MethodInfluentialMeasuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact Scale
Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.supplement_1.s79 · Cited by 1,541 · cited 1×
“Baseline fatigue severity was determined in all randomized patients with the Fisk Fatigue Impact Scale (FFIS) [22].”
MethodDEMITRACK, M. A., DALE, J. K., STRAUS, S. E., LAUE, L., LISTWAK, S. J., KRUESI, M. J. P., CHROUSOS, G. P., & GOLD, P. W. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1224 · Cited by 727 · cited 1×
“The recognition of defective central serotonin neural activity is also observed with nonhepatic disorders such as chronic fatigue syndrome [27].”
BackgroundYounossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999) · Gut · doi:10.1136/gut.45.2.295 · Cited by 670 · cited 9×
“Springer Health-related quality-of-life assessment was performed with the Chronic Liver Disease Questionnaire (CLDQ) [23].”
MethodInfluentialThe presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504 · cited 1×
“Bile duct injury from portal and periportal inflammation often results in progressive fibrosis and eventual cirrhosis [1].”
BackgroundUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationSWAIN, M. G. (2000) · Clinical Science · doi:10.1042/cs0990001 · Cited by 383 · cited 1×
“Both serotonergic and noradrenaline pathways have been implicated [26].”
BackgroundPrince, M., Chetwynd, A., Newman, W., Metcalf, J. V., & James, O. F. W. (2002) · Gastroenterology · doi:10.1053/gast.2002.36027 · Cited by 348
Christensen, E., Crowe, J., Doniach, D., Popper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 273
Parés, A., Caballería, L., Rodés, J., Bruguera, M., Rodrigo, L., García-Plaza, A., Berenguer, J., Rodríguez-Martínez, D., Mercader, J., & Velicia, R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80216-0 · Cited by 271
COMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Impact of fatigue on the quality of life of patients with primary biliary cirrhosis
Huet, P.-M., Deslauriers, J., Tran, A., Faucher, C., & Charbonneau, J. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01857.x · Cited by 262
Fatigue in primary biliary cirrhosis
Cauch-Dudek, K., Abbey, S., Stewart, D. E., & Heathcote, E. J. (1998) · Gut · doi:10.1136/gut.43.5.705 · Cited by 237
The true impact of fatigue in primary biliary cirrhosis: A population study
Goldblatt, J., Taylor, P. J. S., Lipman, T., Prince, M. I., Baragiotta, A., Bassendine, M. F., James, O. F. W., & Jones, D. E. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32993 · Cited by 202
The Demography of Primary Biliary Cirrhosis in Ontario, Canada
Witt-Sullivan, H., Heathcote, J., Cauch, K., Blendis, L., Ghent, C., Katz, A., Milner, R., Pappas, C. S., Rankin, J., & Wanless, I. R. (1990) · Hepatology · doi:10.1002/hep.1840120116 · Cited by 181
Cholestatic liver diseases and health-related quality of life
Younossi, Z. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00833-3 · Cited by 166
Prince, M. I., James, O., Holland, N. P., & Jones, D. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80385-2 · Cited by 141
PRIMARY BILIARY CIRRHOSIS—A REVISED CLINICAL SPECTRUM
Tames, O., MacKlon, A. F., & Watson, A. J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92457-0 · Cited by 137
(1999) · PubMed · Cited by 109
Swain, M. G., Patchev, V, Vergalla, J., Chrousos, G., & Jones, E. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116408 · Cited by 91 · cited 1×
“Swain and colleagues have demonstrated a decrease in hypothalamic CRH concentrations and diminished in vitro release of CRH from hypothalamic explants of rats with obstructive cholestasis [31].”
BackgroundNyberg, A., & Lööf, L. (1989) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528909092240 · Cited by 86
Swain, M. G., & Maric, M. (1995) · Hepatology · doi:10.1002/hep.1840220532 · Cited by 73 · cited 1×
“Furthermore, HPA axis responsiveness is diminished following injection of CRH in cholestatic rats [32, 33].”
BackgroundTheal, J. J., Toosi, M. N., Girlan, L., Heslegrave, R. J., Huet, P., Burak, K. W., Swain, M., Tomlinson, G. A., & Heathcote, E. J. (2005) · Hepatology · doi:10.1002/hep.20698 · Cited by 73 · cited 2×
“Improved fatigue severity was not associated with the use of ondansetron (a 5HT1 A receptor antagonist) versus placebo [20] in a cross-over study.”
BackgroundMethodRelief from profound fatigue associated with chronic liver disease by long‐term ondansetron therapy
Jones, E. A. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02936-0 · Cited by 66 · cited 1×
“In clinical settings, an isolated case report [28] has documented improvement in fatigue with ondansetron (a 5HT1 A receptor antagonist) from a single patient with chronic hepatitis C.”
BackgroundPrince, M. I., Mitchison, H. C., Ashley, D., Burke, D. A., Edwards, N., Bramble, M. G., James, O. F. W., & Jones, D. E. J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01398.x · Cited by 52 · cited 2×
“The empirical use of antioxidant therapy had no effect on fatigue scores in a randomized, placebo-controlled crossover trial [18], despite positive results from an uncontrolled study [19].”
BackgroundChronic cholestasis in rats induces anhedonia and a loss of social interest
Swain, M. G., & Le, T. (1998) · Hepatology · doi:10.1002/hep.510280102 · Cited by 49
Burak, K. W., Le, T. P., & Swain, M. G. (2002) · Gastroenterology · doi:10.1053/gast.2002.31878 · Cited by 48 · cited 1×
“Burak and colleagues also demonstrated increased sensitivity to locomotor activating effects following central CRH infusion [34].”
BackgroundThe Natural History of Primary Biliary Cirrhosis
Kapelman, B., & Schaffner, F. (1981) · Seminars in Liver Disease · doi:10.1055/s-2008-1040731 · Cited by 47
Augmented Interleukin–1β-Induced Depression of Locomotor Activity in Cholestatic Rats
Swain, M. G., Beck, P., Rioux, K., & Le, T. (1998) · Hepatology · doi:10.1002/hep.510280616 · Cited by 43 · cited 1×
“Infusion of IL-1β into cholestatic rodents was noted for increases in lethargy and fatigue, suggesting that liver disease may enhance the central effects of this cytokine [35].”
BackgroundWatson, J. P., Jones, D. E., James, O. F., Cann, P. A., & Bramble, M. G. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01968.x · Cited by 43 · cited 1×
“The empirical use of antioxidant therapy had no effect on fatigue scores in a randomized, placebo-controlled crossover trial [18], despite positive results from an uncontrolled study [19].”
BackgroundAssessing quality of life in primary biliary cirrhosis
Rannard, A., Buck, D., Jones, D. E. J., James, O., & Jacoby, A. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00323-9 · Cited by 35
Endocrine function in multiple sclerosis
Klapps, P., Seyfert, S., Fischer, T. K., & Scherbaum, W. A. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1992.tb04059.x · Cited by 25 · cited 1×
“Abnormal hypothalamic-pituitaryadrenal (HPA) axis function has been documented in patients with rheumatoid arthritis [29] and multiple sclerosis [30].”
BackgroundEarly features of primary biliary cirrhosis: an analysis of 85 patients.
Jp, C., Christensen, E., Doniach, D., Popper, H., Tygstrup, N., & Williams, R. L. (1985) · PubMed · Cited by 20
Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., et al. (1994) · Hepatology · doi:10.1002/hep.1840190512 · Cited by 2
Cited by
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“(184) Fluoxetine, a selective serotonin reuptake inhibitor, also did not improve fatigue.(185) Patients with PBC-related fatigue have excessive daytime sleepiness.”
BackgroundSelf-citationCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Self-citationHohenester, S., Oude-Elferink, R. P. J., & Beuers, U. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 179
“The selective serotonin reuptake inhibitors fluvoxamine and fluoxetine also failed to exert beneficial effects on fatigue in this patient group [311, 312].”
BackgroundPrimary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Metadata
- Authors
- Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Talwalkar, Jayant A.
- ORCID
- Lindor, Keith D.
- Venue
- Digestive Diseases and Sciences
- Published
- 2006-10-20
- Volume
- 51
- Issue
- 11
- Pages
- 1985-1991
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2024885291
- Cited by
- 54
- References
- 35
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- fluoxetine, primary biliary cirrhosis, fatigue, selective serotonin reuptake inhibitors, serotonergic neurotransmission, cholestasis, health-related quality of life, drug adverse events
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Fatigue, Fluoxetine, Humans, Liver Cirrhosis, Biliary, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.